|
Fusion gene ID: 11242 |
FusionGeneSummary for EIF3A_SLCO1B1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: EIF3A_SLCO1B1 | Fusion gene ID: 11242 | Hgene | Tgene | Gene symbol | EIF3A | SLCO1B1 | Gene ID | 8661 | 10599 |
Gene name | eukaryotic translation initiation factor 3 subunit A | solute carrier organic anion transporter family member 1B1 | |
Synonyms | EIF3|EIF3S10|P167|TIF32|eIF3-p170|eIF3-theta|p180|p185 | HBLRR|LST-1|LST1|OATP-C|OATP1B1|OATP2|OATPC|SLC21A6 | |
Cytomap | 10q26.11 | 12p12.1 | |
Type of gene | protein-coding | protein-coding | |
Description | eukaryotic translation initiation factor 3 subunit AEIF3, p180 subunitcentrosomin homologcytoplasmic protein p167eIF-3-thetaeIF3 p167eIF3 p180eIF3 p185eukaryotic translation initiation factor 3 subunit 10eukaryotic translation initiation factor 3 | solute carrier organic anion transporter family member 1B1OATP-2liver-specific organic anion transporter 1sodium-independent organic anion-transporting polypeptide 2solute carrier family 21 (organic anion transporter), member 6 | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | Q14152 | Q9Y6L6 | |
Ensembl transtripts involved in fusion gene | ENST00000369144, ENST00000541549, | ENST00000256958, | |
Fusion gene scores | * DoF score | 6 X 6 X 2=72 | 4 X 3 X 4=48 |
# samples | 6 | 4 | |
** MAII score | log2(6/72*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/48*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: EIF3A [Title/Abstract] AND SLCO1B1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | EIF3A | GO:0001732 | formation of cytoplasmic translation initiation complex | 17581632 |
Hgene | EIF3A | GO:0075522 | IRES-dependent viral translational initiation | 9573242|23766293|24357634 |
Hgene | EIF3A | GO:0075525 | viral translational termination-reinitiation | 21347434 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | AI207430 | EIF3A | chr10 | 120801566 | - | SLCO1B1 | chr12 | 21294366 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-intron | ENST00000369144 | ENST00000256958 | EIF3A | chr10 | 120801566 | - | SLCO1B1 | chr12 | 21294366 | + |
intron-intron | ENST00000541549 | ENST00000256958 | EIF3A | chr10 | 120801566 | - | SLCO1B1 | chr12 | 21294366 | + |
Top |
FusionProtFeatures for EIF3A_SLCO1B1 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
EIF3A | SLCO1B1 |
RNA-binding component of the eukaryotic translationinitiation factor 3 (eIF-3) complex, which is required for severalsteps in the initiation of protein synthesis (PubMed:17581632,PubMed:25849773). The eIF-3 complex associates with the 40Sribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiationcomplex (43S PIC). The eIF-3 complex stimulates mRNA recruitmentto the 43S PIC and scanning of the mRNA for AUG recognition. TheeIF-3 complex is also required for disassembly and recycling ofpost-termination ribosomal complexes and subsequently preventspremature joining of the 40S and 60S ribosomal subunits prior toinitiation (PubMed:17581632, PubMed:11169732). The eIF-3 complexspecifically targets and initiates translation of a subset ofmRNAs involved in cell proliferation, including cell cycling,differentiation and apoptosis, and uses different modes of RNAstem-loop binding to exert either translational activation orrepression (PubMed:25849773, PubMed:27462815). {ECO:0000255|HAMAP-Rule:MF_03000, ECO:0000269|PubMed:11169732,ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773,ECO:0000269|PubMed:27462815}. (Microbial infection) Essential for the initiation oftranslation on type-1 viral ribosomal entry sites (IRESs), likefor HCV, PV, EV71 or BEV translation (PubMed:23766293,PubMed:24357634). {ECO:0000269|PubMed:23766293,ECO:0000269|PubMed:24357634}. (Microbial infection) In case of FCV infection, plays arole in the ribosomal termination-reinitiation event leading tothe translation of VP2 (PubMed:18056426).{ECO:0000269|PubMed:18056426}. | Mediates the Na(+)-independent uptake of organic anionssuch as pravastatin, taurocholate, methotrexate,dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol,estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3,leukotriene E4, thyroxine and triiodothyronine. Involved in theclearance of bile acids and organic anions from the liver.{ECO:0000269|PubMed:10358072, ECO:0000269|PubMed:10601278,ECO:0000269|PubMed:12196548, ECO:0000269|PubMed:22232210}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for EIF3A_SLCO1B1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for EIF3A_SLCO1B1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for EIF3A_SLCO1B1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | SLCO1B1 | Q9Y6L6 | DB01045 | Rifampicin | Solute carrier organic anion transporter family member 1B1 | small molecule | approved |
Tgene | SLCO1B1 | Q9Y6L6 | DB01211 | Clarithromycin | Solute carrier organic anion transporter family member 1B1 | small molecule | approved |
Tgene | SLCO1B1 | Q9Y6L6 | DB05521 | Telaprevir | Solute carrier organic anion transporter family member 1B1 | small molecule | approved|withdrawn |
Top |
RelatedDiseases for EIF3A_SLCO1B1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | EIF3A | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Tgene | SLCO1B1 | C0026848 | Myopathy | 5 | CTD_human |
Tgene | SLCO1B1 | C0041755 | Adverse reaction to drug | 1 | CTD_human |
Tgene | SLCO1B1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |